Study of Duchenne muscular dystrophy long-term survivors aged 40 years and older living in specialized institutions in Japan

Neuromuscul Disord. 2017 Feb;27(2):107-114. doi: 10.1016/j.nmd.2016.11.012. Epub 2016 Nov 25.

Abstract

The national muscular dystrophy wards database of Japan lists 118 long-term Duchenne muscular dystrophy (DMD) patients who were at least 40 years old as of October 1, 2013. To elucidate the clinical features of DMD patients aged 40 years and older, we obtained gene analysis and muscle biopsy findings, as well as medical condition information. Ninety-four of the registered patients consented to participate, of whom 55 meeting genetic or biochemical criteria confirming DMD were analyzed. The mean age at the time of the study was 43.6 ± 3.0 years, while at the time of independent ambulation loss it was 10.6 ± 1.5 years and at mechanical ventilation introduction it was 24.1 ± 5.5 years. All were receiving continuous ventilation support, 27 with non-invasive positive pressure ventilation and 28 with tracheal intermittent positive pressure ventilation. Thirty-eight were receiving β-blockers or a renin-angiotensin system inhibitor, while 9 were free from those agents. Forty had maintained oral nutrition. The 55 analyzed patients had survived into their 40s by receiving multidisciplinary intervention. Our findings emphasize the need of future studies to investigate disease modifiers and the mechanism of long-term survival. In addition, establishment of a worldwide care standard with focus on quality of life for adult males with DMD is important.

Keywords: Conventional multidisciplinary care; Duchenne muscular dystrophy (DMD); Long-term survivor.

Publication types

  • Clinical Trial
  • Observational Study

MeSH terms

  • Adult
  • Cross-Sectional Studies
  • Humans
  • Institutionalization
  • Japan
  • Male
  • Middle Aged
  • Muscular Dystrophy, Duchenne / drug therapy
  • Muscular Dystrophy, Duchenne / physiopathology
  • Muscular Dystrophy, Duchenne / therapy*
  • Survivors